Ultrasensitive test detects biomarkers for specific form of dementia

AI Summary

A newly developed ultrasensitive test is capable of detecting biomarkers associated with specific forms of dementia. As dementia cases continue to rise worldwide, this innovation represents a significant advancement in early diagnosis and management of cognitive health.

Dementia affects over 57 million people worldwide, a number expected to nearly double in the next 20 years. This permanent loss of cognitive abilities affects daily function and can be caused by multiple brain pathologies, including well-known ones like Alzheimer's disease (AD). Right now, biomarkers permit diagnosis of AD, but not rarer pathologies like frontotemporal lobar degeneration (FTLD) or its subtypes.